arrow
Y

Yoko Shibata

fukushima medical university
H指数:43
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders

YKL-40的临床应用价值及其对阻塞性气道疾病病理生理机制的理解

2026-01-010
OAAI
High Serum TSLP Is Characteristic of Late-Onset, Long-Duration, Eosinophilic Asthma

高血清TSLP是迟发型、长病程、嗜酸性粒细胞性哮喘的特征

2025-10-210
PRE
Management of COPD With Cardiovascular Risk in Asia: A Review by the Asian Pacific Society of Respirology COPD Assembly

亚洲心血管风险患者的COPD管理:亚太呼吸学会COPD分会综述

2025-08-110
OAAI
Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review

成功管理由免疫检查点抑制剂诱发的慢性嗜酸性肺炎:一例病例报告及文献综述

2025-07-220
OA
Influence of Educational Films on Antiviral Prescription for COVID-19: Insights from Web-Based Survey in Japan
2025-03-070
OA
Serum YKL-40 as a biomarker for predicting loss of lung function and neutrophilic airway inflammation in asthma, COPD and asthma-COPD overlap
2023-10-271
PRE
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

单细胞分析和宿主遗传学强调先天免疫细胞在新型冠状病毒肺炎严重程度中的作用

2023-04-2418
OAAI
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
2022-12-0518
OAAI
High frequency of HTRA1 AND ABCC6 mutations in Japanese patients with adult-onset cerebral small vessel disease
2022-10-194
OAAI
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force
2022-08-2213
OAAI
Real-world clinical outcomes of treatment with casirivimab- imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
2022-01-014
OAAI
Association Between Sleep Characteristics and Asthma Control in Middle-Aged and Older Adults: A Prospective Cohort Study

中老年睡眠特征与哮喘控制的关系: 一项前瞻性队列研究

2021-04-011
OAAI